Eli Lilly and Company News - September 29, 2026

Lilly Finds Zepbound Linked to More Weight Loss Than High-Dose Wegovy

Eli Lilly (LLY) reported results from an indirect treatment comparison suggesting its weight-loss drug Zepbound was associated with greater weight loss than...

Eli Lilly Says Foundayo Outperformed Novo's Oral Semaglutide in Indirect Comparison

Eli Lilly announced new data suggesting its oral GLP-1 drug Foundayo (orforglipron) provided greater weight loss and blood sugar control than Novo Nordisk's...